RNAZ Transcode Therapeutics
- 0.385
- +0.005+1.18%
- 0.387
- +0.003+0.75%
Transcode Therapeutics News
H.C. Wainwright Maintains Transcode Therapeutics(RNAZ.US) With Buy Rating, Maintains Target Price $3
TransCode Therapeutics Analyst Ratings
H.C. Wainwright Maintains Transcode Therapeutics(RNAZ.US) With Buy Rating, Maintains Target Price $3
Buy Rating for TransCode Therapeutics Backed by NIH Grant and Promising Treatment Efficacy
TransCode Therapeutics Analyst Ratings
TransCode Therapeutics Analyst Ratings
TransCode Therapeutics Analyst Ratings
Analysts' Top Healthcare Picks: Mustang Bio (MBIO), TransCode Therapeutics (RNAZ)
Analysts Offer Insights on Healthcare Companies: TransCode Therapeutics (RNAZ) and Nyxoah (NYXH)
TransCode Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Syros Pharmaceuticals (SYRS), Alpine Immune Sciences (ALPN) and TransCode Therapeutics (RNAZ)
HC Wainwright & Co. Reiterates Buy on TransCode Therapeutics, Maintains $3 Price Target
TransCode Therapeutics Analyst Ratings
Promising Preliminary Clinical and Preclinical Results Bolster Buy Rating for TransCode Therapeutics: An Analysis by Emily Bodnar
TransCode Therapeutics Analyst Ratings
H.C. Wainwright Initiates a Buy Rating on TransCode Therapeutics (RNAZ)
Analysts Offer Insights on Healthcare Companies: TransCode Therapeutics (RNAZ), Tarsus Pharmaceuticals (TARS) and Roivant Sciences (ROIV)
TransCode Therapeutics (RNAZ) Gets a Buy From H.C. Wainwright
H.C. Wainwright Sticks to Its Buy Rating for TransCode Therapeutics (RNAZ)
HC Wainwright Adjusts Price Target on TransCode Therapeutics to $6 From $10, Maintains Buy Rating
Analysis
Price Target
No Data
No Data